MedTrace Logo

Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects

NCT02426151 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2016-03-18

No results posted yet for this study

Summary

To Compare Pharmacokinetic and Pharmacodynamic Profiles of BEPO-A and REPO-A in Healthy Male Subjects

Conditions

  • Healthy

Interventions

DRUG

BEPO-A

BEPO-A (Bioreactor manufacturing process)

DRUG

REPO-A

REPO-A (Roller bottle manufacturing process)

Sponsors & Collaborators

  • LG Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-05-31
Completion
2015-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426151 on ClinicalTrials.gov